GBA1 and synucleinopathy: Preclinical data support that in GBA1 mutant mouse models or synucleinopathy models, viral delivery of GBA1 increased GCase activity, decreased GlcCer/GlcSph, reduced α-syn aggregation and ameliorated behavioural/neurodegenerative changes.